[96a5a0]: / output / allTrials / identified / NCT01148160_identified.json

Download this file

252 lines (252 with data), 9.6 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
{
"info": {
"nct_id": "NCT01148160",
"official_title": "The Correlation of Voriconazole Trough Plasma Levels With Genetic Polymorphism, Efficacy, and Safety Outcomes in Hematologic Malignancy Patients With Invasive Pulmonary Aspergillosis",
"inclusion_criteria": "all items below\n\n* male or female ≥ 15 years of age\n* immunocompromised patients with hematologic disorders\n* patients received voriconazole due to treat proven, probable invasive (pulmonary) aspergillosis\nHealthy volunteers allowed\nMust have minimum age of 15 Years",
"exclusion_criteria": "* severe hepatic dysfunction (t.bil, AST, ALT, ALP > 5 x upper normal limit)\n* who experienced hypersensitivity to azoles\n* pregnant women",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "all items below",
"criterions": [
{
"exact_snippets": "all items below",
"criterion": "all items",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* male or female ≥ 15 years of age",
"criterions": [
{
"exact_snippets": "male or female",
"criterion": "gender",
"requirements": [
{
"requirement_type": "presence",
"expected_value": [
"male",
"female"
]
}
]
},
{
"exact_snippets": "≥ 15 years of age",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 15,
"unit": "years"
}
}
]
}
]
},
{
"line": "* immunocompromised patients with hematologic disorders",
"criterions": [
{
"exact_snippets": "immunocompromised patients",
"criterion": "immunocompromised status",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "hematologic disorders",
"criterion": "hematologic disorders",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* patients received voriconazole due to treat proven, probable invasive (pulmonary) aspergillosis",
"criterions": [
{
"exact_snippets": "patients received voriconazole",
"criterion": "voriconazole treatment",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "treat proven, probable invasive (pulmonary) aspergillosis",
"criterion": "invasive pulmonary aspergillosis",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": [
"proven",
"probable"
]
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 15 Years",
"criterions": [
{
"exact_snippets": "minimum age of 15 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 15,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* severe hepatic dysfunction (t.bil, AST, ALT, ALP > 5 x upper normal limit)",
"criterions": [
{
"exact_snippets": "severe hepatic dysfunction",
"criterion": "hepatic dysfunction",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "severe"
}
]
},
{
"exact_snippets": "t.bil ... > 5 x upper normal limit",
"criterion": "total bilirubin (t.bil)",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 5,
"unit": "x upper normal limit"
}
}
]
},
{
"exact_snippets": "AST ... > 5 x upper normal limit",
"criterion": "aspartate aminotransferase (AST)",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 5,
"unit": "x upper normal limit"
}
}
]
},
{
"exact_snippets": "ALT ... > 5 x upper normal limit",
"criterion": "alanine aminotransferase (ALT)",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 5,
"unit": "x upper normal limit"
}
}
]
},
{
"exact_snippets": "ALP > 5 x upper normal limit",
"criterion": "alkaline phosphatase (ALP)",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 5,
"unit": "x upper normal limit"
}
}
]
}
]
},
{
"line": "* who experienced hypersensitivity to azoles",
"criterions": [
{
"exact_snippets": "hypersensitivity to azoles",
"criterion": "hypersensitivity to azoles",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* pregnant women",
"criterions": [
{
"exact_snippets": "pregnant women",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}